Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease
Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease
复制标题
DOI：
10.1016/s0896-6273(03)00294-0
复制
发表时间：
2003-05-22
期刊：
影响因子：
16.2
通讯作者：
Nitsch, RM
中科院分区：
文献类型：
--
作者：
Hock, C;Konietzko, U;Nitsch, RM
为了测试针对β-淀粉样蛋白的抗体是否能有效减缓阿尔茨海默病的进展，我们在一项安慰剂对照随机试验中评估了30名患者的认知功能，这些患者在1年内接受了聚集的Abeta（42）的初免和加强免疫。20例患者产生抗β-淀粉样蛋白的抗体，通过组织淀粉样蛋白斑块免疫反应性测定确定。与没有这种抗体的患者相比，产生这种抗体的患者显示出认知功能和日常生活活动的下降速率显著较慢，如通过简易精神状态检查、痴呆症残疾评估和韦氏记忆量表延迟回忆的视觉配对联想测试所示。这些有益的临床效果也出现在两个谁经历了短暂发作的免疫相关的无菌性脑膜脑炎的三名患者。我们的研究结果表明，抗β-淀粉样蛋白斑块的抗体可以减缓阿尔茨海默病患者的认知能力下降。
To test whether antibodies against beta-amyloid are effective in slowing progression of Alzheimer's disease, we assessed cognitive functions in 30 patients who received a prime and a booster immunization of aggregated Abeta(42) over a 1 year period in a placebo-controlled, randomized trial. Twenty patients generated antibodies against beta-amyloid, as determined by tissue amyloid plaque immunoreactivity assay. Patients who generated such antibodies showed significantly slower rates of decline of cognitive functions and activities of daily living, as indicated by the Mini Mental State Examination, the Disability Assessment for Dementia, and the Visual Paired Associates Test of delayed recall from the Wechsler Memory Scale, as compared to patients without such antibodies. These beneficial clinical effects were also present in two of three patients who had experienced transient episodes of immunization-related aseptic meningoencephalitis. Our results establish that antibodies against beta-amyloid plaques can slow cognitive decline in patients with Alzheimer's disease.